NEW YORK (GenomeWeb) – Vermillion said yesterday that its Aspira Labs subsidiary has won out-of-state provider status with Medi-Cal, California's Medicaid program, for its OVA1 ovarian cancer test.

The status gives the company access to more than 12 million Medi-Cal beneficiaries, representing roughly one-third of the covered lives in California, Vermillion said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.